Author

D. Atar

3 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Open access Aug 2026

Lipoprotein(a) Inhibition: Current Evidence, Therapeutic Landscape, and Future Directions

Lipoprotein(a) [Lp(a)] is a genetically determined, apolipoprotein B-containing lipoprotein that contributes to cardiovascular risk through atherogenic, proinflammatory, and potentially antifibrinolytic mechanisms. Genetic, epidemiological, and mechanistic evidence supports a causal role for elevated Lp(a) in atheroscl...

P. Sabouret, D. Giamundo, J. Popiołek-Kalisz et al. · Reviews in cardiovascular me... · 0 citations

Sep 2026

Risk-Score Guided Estimation of Absolute Benefit From Beta-blockers after Myocardial Infarction in Patients Without Heart Failure.

AIMS To assess whether a modified clinical risk-score can stratify baseline risk and estimate expected absolute benefit from beta-blocker therapy in post-MI (myocardial infarction) patients with LVEF (left ventricular ejection fraction) ≥40%. METHODS This substudy of the BETAMI-DANBLOCK trial included patients with a...

H. Caglar, T. Holmager, A. Kristensen et al. · European Heart Journal - Qua... · 0 citations

Open access Aug 2026

Digital recruitment and prevalence of screen-detected atrial fibrillation in nationwide patch-based ECG screening: the NORSCREEN randomized clinical trial

Abstract Aims Conventional screening modalities for atrial fibrillation (AF) are often constrained by considerable resource and logistical demands. The randomized controlled NORwegian atrial fibrillation self-SCREENing (NORSCREEN) trial employs a fully digital approach to recruitment and implementation. The aim of this...

M. Boskovic, M. Haraldsen, T. Berge et al. · Europace · 1 citation · ⚡1